ArticleSleep & breathing = Schlaf & Atmung2025
Demographic and modifiable risk factors impacting obstructive sleep apnea comorbidities: a New Orleans case-control study.
Article in Sleep & breathing = Schlaf & Atmung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Therapeutic options for patients with obstructive sleep apnoea: a retrospective review of difficult-to-treat cases in a multidisciplinary approach.BMJ open respiratory research · 2026Article
- Reevaluating C-Reactive Protein for Perioperative Risk Stratification: The Overlooked Role of Sleep Apnea in Cardiac Surgery Outcomes.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeObstructive sleep apnea (OSA) is a prevalent sleep disorder characterized by recurrent upper airway collapse during sleep, leading to intermittent cessation or reduction of breathing. Associated symptoms include snoring and excessive daytime sleepiness. OSA is linked to a range of comorbidities, primarily cardiovascular and metabolic conditions. However, emerging evidence suggests a broader spectrum of associated health issues. This study aimed to investigate the relationship between OSA comorbidities and demographics as well as modifiable risk factors within a New Orleans patient population.
methodsA case-control study encompassing 19,875 patients (313 with OSA, 19,558 without) was conducted. Nominal logistic regression analyzed differences between OSA and non-OSA groups, while prevalence of comorbidities was compared across demographic and modifiable risk factors within each group.
resultsOur findings revealed increased odds of cardiovascular and respiratory disorders among OSA patients compared to controls. OSA risk was elevated in males, middle-aged individuals, individuals with body mass index (BMI) greater than 30, and former smokers. Cardiovascular and metabolic conditions were the most prevalent comorbidities in the OSA group, with additional comorbidities including gastrointestinal, respiratory, psychiatric, and renal disorders.
conclusionThese results highlight the multifaceted health burden associated with OSA. Comprehensive management strategies addressing both well-established and emerging comorbidities are essential for optimizing patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.